Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles
Andreas M. Heilmann(Foundation Medicine (United States)), Rachel Erlich(Broad Institute), Richard S.P. Huang(TGS (United Kingdom)), Brian M. Alexander(Brigham and Women's Hospital), James Creeden(Foundation Medicine (United States)), Jonathan W. Riess(University of California Davis Medical Center), Meghann Hjulstrom(Foundation Medicine (United States)), Margaret E. McLaughlin-Drubin(Brigham and Women's Hospital)
Cited by 9
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805